INT18648

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1986
Last Reported 2010
Negated 2
Speculated 1
Reported most in Abstract
Documents 15
Total Number 16
Disease Relevance 2.26
Pain Relevance 5.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Ptgdr) signal transducer activity (Ptgdr)
Anatomy Link Frequency
basal ganglia 1
afferent neurons 1
anterior pituitary 1
Ptgdr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 155 99.90 Very High Very High Very High
agonist 50 98.86 Very High Very High Very High
Glutamate receptor 1 98.04 Very High Very High Very High
Endogenous opioid 1 97.24 Very High Very High Very High
Opioid 10 97.12 Very High Very High Very High
Morphine 15 96.16 Very High Very High Very High
Substantia nigra 22 95.24 Very High Very High Very High
narcan 8 95.20 Very High Very High Very High
dopamine receptor 6 95.08 Very High Very High Very High
midbrain 7 94.84 High High
Disease Link Frequency Relevance Heat
Disease 87 95.28 Very High Very High Very High
Overactive Bladder 35 88.96 High High
Schizophrenia 52 88.20 High High
Decapitation 1 88.20 High High
Disorders Of The Lacrimal System 1 78.80 Quite High
Diarrhoea 1 78.28 Quite High
Stress 8 78.24 Quite High
Attention Deficit Hyperactivity Disorder 10 77.04 Quite High
Akathisia 1 76.44 Quite High
Pain 1 72.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A single site of binding (K(D) = 14 nM, Bmax = 115 fmol/mg protein) was measured for prostaglandin D2-specific binding to the rat DP receptor.
DP receptor Binding (binding) of
1) Confidence 0.42 Published 1999 Journal Eur. J. Pharmacol. Section Abstract Doc Link 10448933 Disease Relevance 0.07 Pain Relevance 0.26
The present study employed an in vivo binding technique with a tritiated ligand for the D2 receptor ([3H]raclopride) to examine the effects of intraoral milk infusion and opioid manipulations on dopamine activity in the term rat fetus (E21).
D2 receptor Spec (examine) Binding (technique) of associated with dopamine and opioid
2) Confidence 0.33 Published 1993 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 8265693 Disease Relevance 0 Pain Relevance 0.70
Remoxipride was far more potent in preventing [3H]raclopride-binding than [3H]spiperone-binding to the D2 receptor in vivo.
D2 receptor Neg (preventing) Binding (raclopride-binding) of
3) Confidence 0.27 Published 1990 Journal Acta Psychiatr Scand Suppl Section Abstract Doc Link 1978484 Disease Relevance 0 Pain Relevance 0.39
Taken together, these findings suggest that remoxipride acts at both the central D2 and sigma receptors and that its affinity for the D2 receptor is relatively low in vitro.
D2 receptor Binding (affinity) of
4) Confidence 0.26 Published 1990 Journal Acta Psychiatr Scand Suppl Section Abstract Doc Link 1978484 Disease Relevance 0 Pain Relevance 0.22
Additionally, there was no effect of WF-23 treatment on D2 receptor binding, as determined by [3H]spiperone autoradiography.
D2 receptor Binding (binding) of
5) Confidence 0.21 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15617728 Disease Relevance 0 Pain Relevance 0.42
In contrast to the uniform reduction in D2-receptor binding, fluphenazine altered D1-receptor binding in a region-dependent manner.
D2-receptor Binding (binding) of
6) Confidence 0.17 Published 1997 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 9387879 Disease Relevance 0.13 Pain Relevance 0.12
Fluphenazine administration decreased D2-receptor binding throughout the basal ganglia while SCH-23390 was without effect.
D2-receptor Binding (binding) of in basal ganglia
7) Confidence 0.17 Published 1997 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 9387879 Disease Relevance 0.11 Pain Relevance 0.12
The purpose of the present study was to determine the role of D1-receptors in mediating some of these neurochemical events, including changes in D1- and D2-receptor binding, and the expression of preproenkephalin and glutamic acid decarboxylase mRNAs.
D2-receptor Binding (binding) of
8) Confidence 0.17 Published 1997 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 9387879 Disease Relevance 0 Pain Relevance 0.12
All of the R-enantiomers studied showed much weaker affinity for the D2 receptor, as assessed by displacement of [3H]spiperone binding.
D2 receptor Binding (affinity) of
9) Confidence 0.11 Published 1986 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2878816 Disease Relevance 0.07 Pain Relevance 0.25
When tested for its ability to displace [3H]spiperone binding in vitro to a crude fraction of anterior pituitary membranes it was found that it did not compete with the D2 receptor labeled by [3H]spiperone, even at the concentration of 10(-4) M.
D2 receptor Neg (not) Binding (compete) of in anterior pituitary
10) Confidence 0.10 Published 1987 Journal Endocrinology Section Abstract Doc Link 3106018 Disease Relevance 0.14 Pain Relevance 0.25
For D1 binding study, 3H-SCH-23390 was used as ligand and for D2 receptor binding 3H-YM-09151-2 was employed.
D2 receptor Binding (binding) of
11) Confidence 0.09 Published 1995 Journal Pharmacology Section Abstract Doc Link 8584575 Disease Relevance 0.48 Pain Relevance 1.31
Although its affinity for the D2 receptor (Ki = 85 nM) is 4-7 times lower compared to the D1 receptor (Ki = 13 nM) [76], SPD shows much lower or poor affinity for other receptors [35, 84].
D2 receptor Binding (affinity) of
12) Confidence 0.08 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644490 Disease Relevance 0.09 Pain Relevance 0.23
In addition to modulating D1 receptor function, SPD also show the ability to bind to the D2 receptor.
D2 receptor Binding (bind) of
13) Confidence 0.08 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644490 Disease Relevance 0.10 Pain Relevance 0.23
SKF83959 is an atypical agonist of D1-like receptor, and also exhibits moderate or weak affinity to D2 receptor, ?
D2 receptor Binding (affinity) of associated with agonist
14) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948503 Disease Relevance 0.05 Pain Relevance 0.36
These novel neuroleptics display a complex pharmacological profile with affinities for several receptor systems but are generally characterized by a greater affinity for the 5-HT2A receptor than for the target of the traditional neuroleptics, the D2 receptor [4,5].
D2 receptor Binding (affinity) of
15) Confidence 0.05 Published 2001 Journal BMC Pharmacol Section Body Doc Link PMC57001 Disease Relevance 0.86 Pain Relevance 0.11
The results obtained suggest that dopamine may interact with both D1 and D2 receptor subtypes that are most likely located postsynaptically on the afferent neurons, where they may form part of the efferent control of vestibular input [6].
D2 receptor Binding (interact) of in afferent neurons associated with dopamine
16) Confidence 0.01 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2866460 Disease Relevance 0.15 Pain Relevance 0.53

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox